Stentys Revenues for the First Half of 2012 Increase 92% over Prior Year

PRINCETON, N.J. & PARIS--(BUSINESS WIRE)--STENTYS (NYSE Euronext, FR0010949404 – STNT), a medical technology company commercializing the world’s first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), today reports its unaudited revenues for the half year ending 30 June 2012.